Infectious disease following hematopoietic SCT (HSCT) is a major cause of TRM. The more valuable markers to distinguish infections disease from non-infectious complications are needed. Procalcitonin (PCT) and C-reactive protein (CRP) were measured periodically throughout the clinical course of consecutive 28 patients who underwent HSCT. The diagnoses of 103 febrile episodes were analyzed. PCT and CRP level on the first day of fever significantly increased in systemic bacterial or fungal infection (Po0.001 and o0.001, respectively). PCT is more valuable than CRP for discrimination between systemic bacterial or fungal infection and intracellular infection (P ¼ 0.022 and 0.447, respectively). The area under receiver-operator characteristics curve for detection of bacterial or fungal infection was 0.82 for PCT and 0.76 for CRP. When PCT levels did not increase over 0.25 ng/mL through the fifth day of fever, PCT yielded a specificity of 100.0%. In multivariate analysis, the maximum level of PCT during a whole course of HSCT4 ¼ 2 ng/mL was independently associated with worse overall survival as post-transplant predictors (adjusted hazard ratio 6.42, P ¼ 0.035). PCT provide additional information for discrimination between bacterial or fungal infection and other causes and predicting the patient's prognosis after HSCT.
INTRODUCTION
Infectious complications remain a major cause of TRM in hematopoietic SCT (HSCT). The main manifestation of infectious diseases is fever. However, fever appears with several transplantation-related complications beside infectious diseases, such as acute GVHD, engraftment syndrome, thrombotic microangiopathy and relapse of the underlying diseases.
C-reactive protein (CRP) is generally used as a sensitive but not a specific marker of infectious disease, because it rises in various non-infectious complications described above. 1, 2 Thus, more specific markers that enable us to distinguish infections disease from non-infectious complications are needed.
Procalcitonin (PCT) has been recognized as a useful biomarker for diagnosis of bacterial infections with high specificity. 3 --5 In particular, PCT-based algorithm achieved significant reduction of antibiotic exposure in patients with respiratory diseases. 6 --9 Previous studies revealed that high serum PCT level also was associated with not only the diagnosis but also the severity of bacterial and fungal infection in febrile neutropenic patients. 10, 11 However, few studies have been reported whether these findings of PCT are applicable in patients undergoing HSCT. 2,12 --15 In this study, we analyze the clinical value of PCT compared with CRP in patients undergoing HSCT.
PATIENTS AND METHODS Patients
A total of 28 consecutive patients who underwent HSCT in our institution between September and December 2010 were included in the study. The following characteristics were recorded: sex, age, underlying disease, disease status at HSCT, donor types (autologous, related, unrelated or cord blood, and HLA parity), hematopoietic cell transplantation-specific comorbidity index scores, 16 conditioning regimen and GVHD prophylaxis. The hematopoietic cell transplantation-specific comorbidity index score was calculated in each patient and classified into low-risk (score 0), intermediate-risk (score 1 --2) and high-risk (score4 ¼ 3) groups. Patients' diseases were diagnosed according to the WHO classification fourth edition. Disease status was classified into low risk (acute leukemia in the first or second CR, myelodysplastic syndrome in refractory anemia, refractory anemia with ring sideroblasts or refractory cytopenia with multilineage dysplasia, and chemo-sensitive lymphoma and seminoma) and high risk (all the other conditions). All patients gave written informed consent to be enrolled in the clinical study, and this study was performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of the University of Tokyo Hospital.
SCT procedure
For infectious prophylaxis, all patients received levofloxacin 500 mg once a day from admission until neutrophil recovery and fluconazole 200 mg once a day until the end of immunosuppressive drugs. Patients who underwent allogeneic HSCT received 1000 mg acyclovir daily from admission until day 35 and 200 mg daily subsequently as prophylaxis against herpes infections, and sulfa-methoxazole-trimethoprim against Pneumocystis jiroveci infection from the neutrophil engraftment. Both drugs were administered until the end of immunosuppressive drugs. Response-oriented preemptive therapy was used for CMV infection control. 17 All patients received standard supportive care including isolation in laminar flow rooms.
In patients undergoing an allogeneic HSCT, myeloablative conditioning regimens consisted of CY (120 mg/kg) plus fractionated TBI(12 Gy). Non-myeloablative conditioning regimens consisting of fludarabine-based regimens with or without low-dose TBI (4 Gy) were used for the patients who were 455 or received second allogeneic HSCT.
Patients undergoing an autologous HSCT received ranimustine (300 mg/m 18 Acute GVHD was diagnosed and staged according to the Glucksberg score. 19 Pulmonary immunological complication was diagnosed according to the criteria proposed previously. 20 Thrombotic microangiopathy was diagnosed and staged according to the Blood and Marrow Transplant Clinical Trials Network criteria. 21 Engraftment syndrome was diagnosed according to the criteria reported previously. 22 CMV infection was diagnosed by measurement of CMV pp65 antigen in PBMCs. Adenovirus and human herpes virus 6 infection were diagnosed when the antigens or DNA were detected.
When febrile episodes occurred, blood cultures and any relevant clinical samples were obtained. An appropriate imaging test was performed and an empirical broad-spectrum antibiotic treatment was started. If fever persisted and cultures were negative for 3 --5 days, empirical antifungal treatment with micafungin or voriconazole was started after obtaining new samples for cultures.
We classified the febrile episodes in three groups: systemic bacterial or fungal infection, intracellular infection such as viral infection and tuberculosis, and non-infectious febrile episode. The episodes of bacterial or fungal infection were categorized into sepsis, severe sepsis (including septic shock) according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine consensus conference 23 to analyze the relationship between the severity of infectious episodes with PCT and CRP.
PCT and CRP measurements Serum levels of PCT and CRP were measured three times a week from the start of conditioning to the discharge or death. For each episode of fever, we took additional measurement of PCT and CRP within 24 h from the onset of fever, and they were denoted as O-PCT and O-CRP, respectively. We also analyzed the maximum level of PCT (Max-PCT) and CRP (Max-CRP) during each febrile event. In addition, Max-PCT and Max-CRP during a whole course of HSCT were assessed for their impact on transplant outcomes. The serum PCT levels were measured using the fully automated chemiluminescent enzyme immunoassay reagent 'SphereLight---BRAHMS PCT' by a SphereLight Wako (Wako Pure Chemical Industries, Osaka, Japan) and CRP by CRP II Latex X2 (Denka-Seiken, Tokyo, Japan). Reference values were o0.5 ng/mL for PCT and o0.3 mg/dL for CRP.
Statistical analysis
Categorical variables were compared using the Fisher's exact test. Differences of numerical variables between two groups were assessed by the Wilcoxon rank-sum test and among multiple groups by the Kruskal --Wallis test with subsequent pair-wise comparisons with the SteelDwass method. The level of significance was defined as two-tailed (Po0.05). The diagnostic relevance was estimated as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Levels of sensitivity were plotted against the levels of 1-specificity at each cutoff level on a receiver-operator characteristic curve. The overall survival (OS) was estimated with the Kaplan --Meier method, and the impact on OS was analyzed with log-rank test for univariate analysis and Cox proportionalhazards models for multivariate analysis. For univariate analyses, we included pre-transplant risk factors including disease status, hematopoietic cell transplantation-specific comorbidity index score, donor type (autologous or allogeneic), and post-transplant factors including engraftment, acute GVHD of grade II to IV, neutropenic duration (ANC o500/ mm3)4 ¼ 10 days, Max-PCT4 ¼ 2 ng/mL and Max-CRP4 ¼ 10 mg/dL.
The post-transplant factors were analyzed as time-dependent covariates. The factors that showed significance level Po0.10 in univariate analysis were subjected to multivariate analysis. Statistical analysis was performed by JMP Statistical Discovery Software 9.0 (SAS Institute, Cary, NC, USA) and R version 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Patient characteristics and clinical events
The basic characteristics of the patients and transplantation are described below. Underlying diseases were AML and myelodysplastic syndrome (n ¼ 11), ALL (n ¼ 4), non-Hodgkin lymphoma (n ¼ 8) and others (n ¼ 5). A total of 14 patients were at high risk of relapse when they received HSCT and the remaining 14 were at low risk. Hematopoietic cell transplantation-specific comorbidity index score was 0, 1 or 2, 4 ¼ 3 in 14, 7 and 7 patients, respectively. In all, 20 patients received allogeneic HSCT and 8 received autologous HSCT. The conditioning regimens for allogeneic HSCT were myeloablative in 11 and reduced in 9 patients. GVHD prophylaxis consisted of short-term MTX combined with either of FK506 in 4 cases and CYA in 16 cases. It is of note that no patients received anti-thymocyte globulin as GVHD prophylaxis or treatment because this agent can confer false positivity of PCT results. 24 The median follow-up period for survivors was 101 days (range: 11 --178 days). We diagnosed 103 febrile episodes and they were classified as follows: systemic bacterial or fungal infections (n ¼ 30), intracellular infections (n ¼ 7) and non-infectious febrile episodes (n ¼ 67). The detailed etiology of each episode is described in Table 1 .
Analysis of PCT and CRP levels according to clinical events
The serum O-PCT and O-CRP levels were compared among different etiology of fever ( Figure 1 ). The Kruskal --Wallis test showed significant differences between systemic bacterial or fungal infection and the rest in O-PCT and O-CRP levels (Po0.001 and o0.001, respectively). Although pair-wise comparisons corrected for multiple testing showed no significant difference in O-CRP levels between systemic bacterial or fungal infection and intracellular infection (P ¼ 0.447), there was a significant difference between the two groups in O-PCT levels (P ¼ 0.022). Both O-PCT and O-CRP were significantly higher in cases of systemic bacterial The clinical role of procalcitonin in HSCT J Koya et al or fungal infection when compared with non-infectious febrile episode (Po0.001 and o0.001, respectively; Figure 1 ). Subsequently, we divided the febrile episodes into neutropenic fever and non-neutropenic fever. In each group, there was a significant differences between systemic bacterial or fungal infection and the rest in O-PCT levels (Po0.001 for neutropenic fever and Po0.001 for non-neutropenic fever) and in O-CRP levels (Po0.001 for neutropenic fever and P ¼ 0.014 for non-neutropenic fever).
In cases of the systemic bacterial or fungal infection, there were 13 events of sepsis and 17 events of severe sepsis (including septic shock). The median days to maximum value of PCT and CRP were both 2 days (range: 0 --5 and 0 --7 days, respectively). Although O-CRP was only marginally higher in severe sepsis than in nonsevere sepsis (P ¼ 0.049, Figure 2a) , O-PCT values were explicitly different between the two categories (P ¼ 0.002, Figure 2c ). We next examined the maximum value of PCT and CRP during each febrile episode. Max-PCT was apparently higher in severe sepsis than in normal sepsis (P ¼ 0.003, Figure 2d) , however, there were no significant differences in Max-CRP levels between the two categories (P ¼ 0.116, Figure 2b ).
Discrimination between bacterial or fungal infection and other events The discriminatory power of PCT and CRP for the detection of bacterial or fungal infection was analyzed in terms of the area under receiver-operator characteristic curve. As shown in Figure 3 , O-PCT was a superior test for bacterial or fungal infection (area under receiver-operator characteristic curve was 0.82 for O-PCT and 0.76 for O-CRP). Diagnostic cutoff levels with the optimal sensitivity and specificity were 0.5 ng/mL for O-PCT and 4.0 mg/dL for O-CRP. Combining O-PCT (over 0.5 ng/mL) and O-CRP (over 4.0 mg/dL) improved the specificity from 58.9 --70.0% and the PPV from 45.5 --67.7%. The sensitivities, specificities, PPV and NPV of O-PCT and O-CRP for distinguishing bacterial or fungal infections from other events were shown in Table 2 . The specificity and the PPV were also improved by combining O-PCT and O-CRP in neutropenic fever (from 51.1 to 63.2% for the specificity and from 42.5 to 66.7% for the PPV). Next, we tested whether persistently low PCT values could exclude the diagnosis of systemic bacterial or fungal infection. For various cutoff levels of the maximum value from onset of fever to the fifth day, we calculated sensitivity, specificity, PPV and NPV for precluding systemic bacterial or fungal infection. The result is shown in Table 3 . These results show that if a patient's PCT level remained o0.25 ng/mL for the first 5 days of fever, we can exclude the systemic bacterial or fungal infection as an etiology of the fever with a sensitivity of 41.0%, a specificity of 100.0%, a PPV of 100.0% and a NPV of 58.9%.
Impact of PCT on transplant outcomes
The estimated OS according to Max-PCT during HSCT was significantly different between the patients whose Max-PCT increased 2.0 ng/mL or more and o2.0 ng/mL (log-rank test, P ¼ 0.001; Figure 4 ). To take other parameters that would influence the OS into consideration, we conducted a multivariate analysis ( Table 4 ). Univariate analysis showed that Max-PCT4 ¼ 2 ng/mL (P ¼ 0.003), Max-CRP4 ¼ 10 mg/dL (P ¼ 0.004), non-engraftment (P ¼ 0.061), neutropenia duration4 ¼ 10 days (P ¼ 0.002), allo-HSCT (P ¼ 0.011, against auto-HSCT) and high-risk disease status at HSCT (P ¼ 0.071) was associated with poor OS. (Table 4) .
DISCUSSION
Our results showed the PCT levels are useful in differential diagnosis of fever, determining the severity of systemic bacterial or fungal infection and identifying of patients at high risk for TRM compared with the CRP level in patients undergoing HSCT. In addition, this study revealed low PCT performs as a highly specific marker for the exclusion of systemic bacterial or fungal infection by periodical measure of PCT levels throughout a febrile episode. Previous studies revealed that PCT level was a sensitive indicator of bacterial sepsis in immunocompromised and neutropenic patients.
10,11 However, Blijlevens et al. and Ortega et al. 12, 13 revealed PCT was of little value in discriminating infections from other transplantation-related complications occurring following HSCT. In addition, Hambach et al.
14 demonstrated that the diagnostic value of PCT was not superior to that of CRP in the detection of bacterial or fungal infection after HSCT. In our study, however, PCT had a superior discriminatory power to CRP for the detection of systemic bacterial or fungal infection. One explanation for this discrepancy could be the definition of infection. We categorized a febrile episode as bacterial infection only when microbial pathogen was proven. Most of the previous studies included cases of clinically defined infection that was diagnosed without proven microbial pathogen in infectious episodes. Therefore, we may not comprehend mild bacterial infections that are responsive to empirical antibiotics. In addition, although the incidence of febrile event was relatively higher than the other reports, we confirmed 43 days of defervescence between febrile events and could classify the febrile episodes into specific diagnosis except 15% of fever of unknown origin.
In accordance with the previous studies, the PCT levels did not significantly increase in cases of aGVHD and CMV infection. 2, 12, 14, 15 Similarly, we also demonstrated that the O-PCT levels significantly elevated in cases of systemic bacterial or fungal infection compared with other causes. Especially, like the previous study in pediatric patients, 25 our study verified that O-PCT is more valuable than O-CRP for discrimination between systemic bacterial or fungal infection and intracellular infection. Several prior studies revealed the PCT level less increases in intracellular infection by Mycobacterium tuberculosis, Mycoplasma, P. jiroveci, and viruses. 26, 27 Moreover, similar to Hambach et al. Previous studies showed that PCT was valuable for predicting bacteremia in neutropenic patients with sensitivity of 40 --83%, and specificity of 60 --96%. 3, 11, 28 We revealed that PCT had a similar discriminatory power for the detection of systemic bacterial or fungal infection regardless of neutrophils counts at the onset of fever. In addition, our study also revealed that the specificity and the PPV improved by combining O-PCT and O-CRP in case of neutropenic fever.
Several studies revealed that PCT was a better serum marker than CRP for detecting life-threatening infectious event in immunocompromised and neutropenic patients. 14, 15 Especially, Sauer et al. and Semeraro et al. 29, 30 reported that median concentrations of PCT correlated with the severity of sepsis and provided more useful prognostic information during septic episodes than CRP and endotoxin. Likewise, we demonstrated that O-PCT and Max-PCT levels had stronger correlation with the severity of the systemic bacterial or fungal infection than O-CRP and Max-CRP level. In addition, to our knowledge, this is the first report that found Max-PCT is the independent post-transplant prognostic factor after HSCT. One of the most intriguing results in our study was a high specificity and PPV for the exclusion of systemic bacterial or fungal infection when PCT levels did not increase over 0.25 ng/mL for the first 5 days of a febrile episode. In the field of lower respiratory infections, PCT-based algorithm achieved significant reduction of antibiotic exposure and antibiotic-associated adverse effects without increasing rate of adverse outcomes. 6 --9 According to these studies, initiation or continuation of antibiotics was strongly discouraged if PCT was o0.1 ng/mL and discouraged if levels were 0.25 ng/mL or lower. Initiation or continuation of antibiotics was strongly encouraged if PCT was 40.5 ng/mL and encouraged if levels were 40.25 ng/mL. If antibiotics were withheld, PCT measurements were repeated after 3, 5 and 7 days and antibiotic treatment was discontinued using the same cutoff ranges. However, in cases of HSCT recipients, we should be discrete enough not to spare antibiotics in febrile episodes based on PCT values only. Although PCT may also contribute to suppress overuse of broad-spectrum antibiotics, antibiotic-associated adverse effects and the emergence of drug-resistant bacteria in field of hematological malignancy such as neutropenic fever during chemotherapy and transplantation-related complications, it is premature to change the practice of antibiotic usage in febrile neutropenic patients only on grounds of PCT. Guidelines published by the Infectious Diseases Society of America for the use of antimicrobial agents in neutropenic patients recommend reassessment of the patient's condition after 3 --5 days, upon administering broad-spectrum antibiotics. 31 Although this reassessment includes a review of all previous culture results, chest radiography, ascertaining the status of vascular catheters, additional cultures of blood samples and specimens of specific sites of infection and diagnostic imaging of any organ suspected of having infection, we propose that dynamic PCT levels until the day of reassessment should be included to identify the sources of transplantation-related complications and initiate early and appropriate treatment.
In conclusion, serum PCT levels provide additional information for discrimination between bacterial or fungal infection and other causes, estimating the severity of infection and predicting the patient's prognosis after HSCT by periodical measurement throughout a febrile episode. The etiologies other than bacterial or fungal infection should be considered as an origin of fever in the absence of increase in PCT level at any time for the first 5 days of each febrile episode in patients undergoing HSCT. 
